TransCode Therapeutics (RNAZ) Stock Price
$8.72 4.3%
to add to portfolio
AI Score
-
Alternative
6 -
Fundamental
2 -
Technical
2
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on TransCode Therapeutics, AI stock picks, stock alerts and much more.
RNAZ AI Stock Analysis
AI stock analysis for RNAZ is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like TransCode Therapeutics (RNAZ) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
TransCode Therapeutics (RNAZ) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of TransCode Therapeutics (RNAZ), currently trading at $8.72, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About RNAZ
-
TransCode Therapeutics, Inc.
-
Symbol
RNAZ
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
7.3M
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$20.95 3.1% |
7 |
 |
Inovio Pharmaceuticals INO |
$1.31 3.7% |
2 |
 |
Moderna MRNA |
$31.58 3.9% |
3 |
 |
Anavex Life Sciences AVXL |
$10.87 5.3% |
5 |
 |
BridgeBio Pharma BBIO |
$46.97 1.5% |
7 |
News
RNAZ Alternative Data
Web Traffic
TransCode Therapeutics receives an estimated 2148 monthly visitors to transcodetherapeutics.com, which is up by 84.4% over the last month.
-
Web Traffic
2148
-
Change from Previous Month
84.4%
-
3 Month Change
59.2%
-
YoY Change
59.2%
Twitter Followers
TransCode Therapeutics has 359 Twitter Followers on its main Twitter (also known as X) account, which is down by -0.6% over the last month.
-
Twitter Followers
359
-
Daily Change
0.3%
-
1 Month Change
0.6%
-
3 Month Change
4.7%
-
YoY Change
4.7%
LinkedIn Followers
2,165 are following TransCode Therapeutics on LinkedIn, up by 1% over the last month.
-
LinkedIn Followers
2165
-
Daily Change
0.1%
-
1 Month Change
1%
-
3 Month Change
4.7%
Job Postings
TransCode Therapeutics currenly has an estimated 0 open job postings.
-
Job Postings
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
LinkedIn Employees
According to LinkedIn, TransCode Therapeutics has 14 employees, up by 7.7% over the last month.
-
LinkedIn Employees
14
-
Daily Change
0%
-
1 Month Change
7.7%
-
3 Month Change
7.7%
-
YoY Change
7.7%
Reddit Mentions
TransCode Therapeutics has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
News Mentions
TransCode Therapeutics was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
RNAZ Financials
RNAZ Key Metrics
-
Total Revenue
$0
-
Net Income
-$2.3M
-
Earnings per Share
-$0.16
-
Free cash flow
-$3.9M
-
EBITDA
-$2.2M
-
EBITDA Ratio
0
-
Total Assets
$7.3M
RNAZ 2-year Revenue & Income
RNAZ 2-year Free Cash Flow
RNAZ Technicals
RNAZ SMA
RNAZ RSI
FAQ
What's the current price of TransCode Therapeutics (RNAZ) Stock?
The price of an TransCode Therapeutics (RNAZ) share is $8.72.
What's the market cap of TransCode Therapeutics?
The current market cap of TransCode Therapeutics is 7.3M.
Should I buy or sell RNAZ?
TransCode Therapeutics shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, TransCode Therapeutics is better viewed as a hold or accumulate position while waiting for further developments.
Is TransCode Therapeutics a good investment?
The current analysis of TransCode Therapeutics' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in TransCode Therapeutics' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy TransCode Therapeutics (RNAZ) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for TransCode Therapeutics stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to TransCode Therapeutics (RNAZ) that investors often compare it to?
TransCode Therapeutics (RNAZ) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for TransCode Therapeutics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast TransCode Therapeutics' stock price to be around $8.35 in 2026. Starting from the current price of $8.72, this represents a 4.3% change in price, indicating a bearish outlook for the stock.
How to buy TransCode Therapeutics (RNAZ) Stock?
TransCode Therapeutics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy TransCode Therapeutics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.